# A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

> **NCT00420823** · PHASE2,PHASE3 · COMPLETED · sponsor: **Melbourne Health** · enrollment: 121 (actual)

## Conditions studied

- Psychotic Disorders

## Interventions

- **DRUG:** Taurine 4g

## Key facts

- **NCT ID:** NCT00420823
- **Lead sponsor:** Melbourne Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-12
- **Final completion:** 2010-12
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2015-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420823, "A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00420823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*